Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
Alarico ArianiSimone ParisiPatrizia Del MedicoAntonella FarinaElisa VisalliAldo Biagio Molica ColellaFederica LumettiRosalba CaccavalePalma ScolieriRomina AndraccoFrancesco GirelliElena BraviMatteo ColinaAlessandro VolpeAurora IannielloVeronica FranchinaIlaria PlatèEleonora Di DonatoGiorgio AmatoCarlo SalvaraniGianluca LucchiniFrancesco De LuciaFrancesco Molica ColellaDaniele SantilliGiulio FerreroAntonio MarchettaEugenio ArrigoniFlavio MozzaniRosario FotiGilda SandriVincenzo BruzzeseMarino ParoliEnrico FusaroAndrea BeccioliniPublished in: Clinical rheumatology (2022)
Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points • Apremilast retention rates in this real-life cohort and trials are comparable. • The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years). • No different or more prevalent adverse events were observed.